Andrew Krystal, MD

Post hoc Analysis of the Efficacy and Safety of Lemborexant in Adults with Insomnia Disorder and Depression History

Introduction: Study 303 (SUNRISE-2; NCT02952820) evaluated lemborexant (LEM) efficacy in subjects with insomnia. This post-hoc analysis examined sleep outcomes in the subgroup of subjects...

Larry Culpepper , MD;

Andrew Krystal , MD;

Jane Yardley , PhD;

Kate Pinner , MSc;

Naoki Kubota ;

Margaret Moline , PhD;

Jess Amchin , MD, JD;

Norman Atkins Jr., MBA, PhD;

Manoj Malhotra , MD;

Andrew Nierenberg , MD, MGH;

10/08/2020

Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients With Treatment-Resistant Depression in SUSTAIN-2 (NCT02497287)

We assessed potential withdrawal symptoms in patients with treatment-resistant depression (TRD) after long-term, intermittent use of intranasal esketamine (ESK). Patients received ESK 2X/...

Allitia DiBernardo , MD;

Ewa Wajs , MD, PhD;

Andrew Krystal , MD;

Lynn Yieh , PhD;

Ella Daly , MB, BCh, BAO;

Leah Aluisio , PhD;

Wayne Drevets , MD;

Yun Wu , PhD;

Jaskaran Singh , MD;

Peter Zannikos , PhD;

Jagadish Gogate , PhD;

Valerie Curran , PhD;